Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Aurobindo Pharma's API unit clears USFDA inspection with two observations
Aurobindo Pharma announced that the United States Food and Drug Administration (USFDA) had completed an inspection at its wholly owned subsidiary, Auroactive Pharma, located in Andhra Pradesh.
Aurobindo Pharma subsidiary completes US FDA inspection with two observations
Aurobindo Pharma reports US FDA inspection at Auroactive Pharma Srikakulam facility, notes two observations with no impact on financials or operations.
USFDA inspects Auroactive Pharma's manufacturing unit in Andhra Pradesh
Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) conducted an inspection at Auroactive Pharma (a wholly owned subsidiary of the Company), which manufactures Active Pharmaceutical Ingredients (API) & Pharmaceutical Formulation Intermediates, situated at Sy Nos 231, 285 to 291, Sancham Village, Ranasthalam Mandal, Srikakulam District, 523 409, Andhra Pradesh, from 22 June 2026, to 26 June 2026.
Stocks to buy: Aurobindo Pharma, Delhivery, Ather Energy, says Ajit Mishra
Market outlook by Ajit Mishra: The analyst from Religare Broking expects Nifty to consolidate in the near-term; among stocks he recommends Delhivery, Ather Energy and Aurobindo Pharma.
Indian pharma firms gear up to supply key cancer drug to US
Indian drugmakers are stepping up to help the US combat a critical shortage of ifosfamide injection, a vital chemotherapy drug. Leading companies like Zydus, Cipla, Alkem, and Aurobindo Pharma are in discussions to supply the medicine. The US FDA has reached out to Indian pharmaceutical bodies, seeking manufacturers capable of producing the drug in various strengths to ensure availability for cancer patients.
Aurobindo Pharma receives FTC nod for $250 million acquisition of Lannett Company
Aurobindo Pharma announced that its wholly owned subsidiary, Aurobindo Pharma USA, Inc., has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC.
Aurobindo Pharma USA receives US FTC approval for acquisition of Lannett
Aurobindo Pharma USA, Inc. (Aurobindo USA), a wholly owned subsidiary of the Company, today announced that it has received approval from the U.S. Federal Trade Commission (FTC) to proceed with the acquisition of Lannett Company LLC (Lannett).
Stock Picks Today: RIL, Aurobindo Pharma, IOCL, BPCL, Container Corp, And More On Brokerages' Radar
Brokerages' Radar
Aurobindo Pharma US gets FTC nod for $250 million acquisition of Lannett Company
Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic move, expected to conclude by June 2026, will bolster Aurobindo's complex generics and controlled substances portfolio, enhance its US manufacturing capabilities with Lannett's Indiana facility, and is projected to immediately boost earnings per share.
Aurobindo Pharma shares in focus after Eugia Steriles unit gets USFDA observations
The US FDA conducted a Pre-Approval Inspection (PAI) at Eugia Steriles, a wholly-owned subsidiary of Eugia Pharma Specialities Ltd. and a step-down subsidiary of Aurobindo Pharma, located in Parawada Mandal, Anakapalli district of Andhra Pradesh.
Aurobindo Pharma subsidiary Eugia Steriles faces five US FDA observations
Shares of Aurobindo Pharma Ltd ended at ₹1,493.60, down by ₹50.55, or 3.50%, on the BSE.
Aurobindo Pharma shares gain on US FTC nod for Lannett deal; Here's what it needs to do
According to management, the products being divested contribute an estimated $5 million to $10 million in annual revenue, implying a limited financial impact from the sale.